The Pharmacology Center

Filter Your Results

 

News

 

Medtronic Initiates Global Study of 1-Month DAPT After Implantation of Resolute Onyx DES

August 14, 2017 -- Medtronic announced a global randomized clinical trial that will evaluate 1-month dual antiplatelet therapy (DAPT) in patients who have undergone implantati…

Emerging Options for Anticoagulation in LAA Closure

Jessica Tilton, PharmD, BCACP; John Shilka, PharmD; Adhir Shroff, MD, MPH; and Vicki Groo, PharmD

July/August 2017—Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device.

Abbott Vascular Initiates XIENCE Short DAPT Clinical Trial

July 25, 2017 -- Abbott Vascular announced that the first patient has been enrolled in a clinical study evaluating the short-term use of dual antiplatelet therapy (DAPT) after…

IRIS-MAIN Evaluates Differential Event Rates for Treatments of Unprotected Left Main CAD Patients

July 24, 2017 -- Findings from the Interventional Research Incorporation Society-Left Main Revascularization registry (IRIS-MAIN) were recently published online by Se Hun Kang…

Meta-Analysis Compares Short- and Long-Term DAPT After DES Implantation

July 10, 2017 -- The Society for Cardiovascular Angiography and Interventions (SCAI) announced the publication of an investigation evaluating the long-term efficacy and safety…

FDA Approves Bevyxxa for Hospital and Extended-Duration VTE Prevention in Acutely Ill Patients

June 28, 2017 -- Portola Pharmaceuticals Inc. recently announced that the US Food and Drug Administration (FDA) has approved Bevyxxa (betrixaban) for hospital and extended-dur…

FDA Grants Priority Review of 10-mg Dose of Xarelto to Reduce Risk of Recurrent VTE

June 28, 2017 -- Janssen Research & Development, LLC announced that the US Food and Drug Administration (FDA) accepted for priority review a supplemental new drug applicat…

Study Finds No Difference in Outcomes of Transradial PCI in STEMI Patients Treated With Bivalirudin Versus Heparin

June 12, 2017 -- Ion S. Jovin, MD, et al published a report from the National Cardiovascular Data Registry (NCDR) that evaluated bivalirudin versus heparin as anticoagulant ag…

 

advertisement

2017 Buyer’s Guide

This Buyer’s Guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.

 
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.